Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Alzheimer's DiseaseDementia
Interventions
DRUG

Drug: EVP-6124

DRUG

Placebo

Trial Locations (82)

Unknown

Phoenix

Tucson

Costa Mesa

Encino

Glendale

Long Beach

Redding

San Diego

Atlantis

Brooksville

Delray Beach

Fort Myers

Lake Worth

Miami

Orlando

St. Petersburg

Weston

Columbus

Douglasville

Chicago

Park Ridge

Baton Rouge

Bangor

Chestnut Hill

Plymouth

Flowood

Creve Coeur

Princeton

Springfield

Brooklyn

Latham

New York

Staten Island

Wilmington

Columbus

Portland

Norristown

Philadelphia

San Antonio

Wichita Falls

Murray

Salt Lake City

Bennington

Williamsburg

Hornsby

Geelong

West Heidelberg

Brussels

Leuven

Saint Truiden

Kelowna

Chatham

Toronto

Gatineau

Nice

Paris

Rouen

Toulouse

Achim

Cologne

München

Nuremberg

Brescia

Milan

Guadalajara

Monterrey

Bialystok

Bydgoszcz

Poznan

Warsaw

Bellville

Johannesburg

Pretoria

Somerset West

Seongnam-si

Busan

Seoul

Elche

Barcelona

Terrassa

Madrid

Burgos

Sponsors
All Listed Sponsors
lead

FORUM Pharmaceuticals Inc

INDUSTRY